Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

Joseph B. Domachowske,Yue Chang,Victoria Atanasova,Fernando Cabanas,Kenji Furuno,Kim A. Nguyen, Irfana Banu,Robert J. Kubiak,Amanda Leach,Vaishali S. Mankad,Manish Shroff,Therese Takas,Tonya Villafana,Ulrika Wahlby Hamren

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY（2023）

Cited 1|Views18
No score
Abstract
In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.
More
Translated text
Key words
monoclonal antibody,nirsevimab,pharmacokinetics,palivizumab,respiratory syncytial virus
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined